Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Non-myeloablative transplantation.

David G Maloney1, Brenda M Sandmaier, Stephen Mackinnon

  • 1Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA.

Hematology. American Society of Hematology. Education Program
|November 26, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pre- and post-transplant serum albumin levels and outcomes after allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia.

Leukemia & lymphoma·2026
Same author

Case Report: donor cell-derived leukemia after allogeneic stem cell transplantation for metastatic renal cell carcinoma.

Frontiers in immunology·2026
Same author

[211At]Astatine-Based Conditioning with a Humanized CD45 Antibody for Autologous Hematopoietic Stem Cell Gene Therapy.

Blood·2026
Same author

Autologous and allogeneic hematopoietic cell transplantation in children and adults with high-risk anaplastic large cell lymphoma.

Frontiers in oncology·2026
Same author

Comparative In Vitro Evaluation of Anti-HIV Immunotoxin, Antibody-Drug Conjugate, and Radioimmunoconjugate Targeted by the Same Antibody.

Antibodies (Basel, Switzerland)·2026
Same author

In vitro evaluation of anti-HIV radioimmunoconjugates labeled with astatine-211, thorium-227 and actinium-225.

Nuclear medicine and biology·2026
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Nonmyeloablative allogeneic stem cell transplantation uses enhanced immunosuppression for engraftment, reducing early mortality. This approach leverages graft-versus-host responses for tumor eradication, offering a curative option for vulnerable patients.

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Traditional myeloablative conditioning for allogeneic stem cell transplantation carries significant early mortality and morbidity.
  • Enhanced immunosuppression allows stem cell engraftment with reduced early transplant-related mortality (TRM).
  • This strategy shifts tumor eradication to graft-versus-host (GVH) immune responses against tumor cells.

Purpose of the Study:

  • To review the current applications of nonmyeloablative allogeneic stem cell transplantation for various hematologic malignancies.
  • To discuss tandem transplant approaches combining autologous and nonmyeloablative allografts.
  • To explore strategies for preventing graft-versus-host disease (GVHD) while preserving graft-versus-tumor (GVT) activity.

Main Methods:

Related Experiment Videos

  • Review of nonmyeloablative regimens for chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), acute leukemia, myelodysplastic syndromes (MDS), lymphoma, and myeloma.
  • Discussion of autologous transplantation followed by planned non-myeloablative allografts for myeloma and non-Hodgkin lymphoma (NHL).
  • Analysis of T cell depletion strategies and donor lymphocyte infusions (DLIs) to modulate GVHD and GVT.

    • Main Results:

    • Nonmyeloablative regimens enable stem cell engraftment with lower early TRM, making transplantation accessible to elderly or infirm patients.
    • Tandem autologous-allogeneic transplantation demonstrates lower TRM compared to conventional high-dose allografting.
    • The GVT response in nonmyeloablative allografts may target minimal residual disease, potentially preventing relapse in NHL and myeloma.

    Conclusions:

    • Nonmyeloablative allogeneic transplantation offers a potentially curative approach with reduced early risks, expanding treatment options for hematologic cancers.
    • Strategies to separate GVHD from GVT activity are crucial for improving the safety and efficacy of this procedure.
    • Future research focusing on immunization or T cell cloning could further enhance nonmyeloablative allogeneic transplantation outcomes.